
In today’s briefing:
- Amgen: How Its $3.5 Billion Acquisition & Its High-Stakes Drug Pipeline Are Reshaping Its Growth Strategy
- Regeneron Pharmaceuticals: Libtayo Expansion To Up Their Oncology Game!
- Sionna Therapeutics Inc. (SION): RA Capital Backed Biotech IPO Booms in Debut

Amgen: How Its $3.5 Billion Acquisition & Its High-Stakes Drug Pipeline Are Reshaping Its Growth Strategy
- Amgen Inc. highlighted substantial achievements and growth potential for 2024 while outlining some challenges and strategies moving forward.
- The company’s financial results reflected its success across various therapeutic areas, despite facing pricing pressures and patent expirations.
- Revenue for the full year of 2024 reached $33.4 billion, reflecting a significant 19% increase year-over-year, driven mainly by a 23% volume increase across products.
Regeneron Pharmaceuticals: Libtayo Expansion To Up Their Oncology Game!
- Regeneron Pharmaceuticals presented its fourth-quarter 2024 results, revealing a 10% year-over-year revenue growth, driven by strong performances from key product lines such as Dupixent, EYLEA, and Libtayo.
- Dupixent, in particular, has become a blockbuster treatment in multiple indications, showing robust uptake across the globe with more than 1 million patients currently benefiting from the drug in various approved applications.
- However, the performance of EYLEA was noted in a competitive landscape, with the company focused on increasing the market share of EYLEA HD through upcoming product enhancements like prefilled syringe options and extended dosing intervals.
Sionna Therapeutics Inc. (SION): RA Capital Backed Biotech IPO Booms in Debut
- Biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis opened its IPO 39% above issue.
- The transaction was upsized from 8.8mm shares to 10.6mm shares and priced at the high-end of the range.
- The IPOs that are more apt to see “follow-through” in the aftermarket are those with product candidates in later stage. This IPO does not meet that criteria.